Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.42 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | PRKDC | P78527 | 3/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371276 | 0.85 | PIK3CD (0.49) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL359707 | 0.82 | PIK3CD (0.51) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL357452 | 0.77 | PIK3CD (0.61) | PIK3CDPIK3CA | |
| SCHEMBL2276963 | 0.75 | PIK3CD (0.68) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL2392521 | 0.72 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL358620 | 0.71 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R1 | |
| SCHEMBL2273668 | 0.70 | PIK3CD (0.72) | PIK3CDPIK3CAPIK3CBPIK3CGCYP3A4 | |
| SCHEMBL360139 | 0.70 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL358650 | 0.70 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL358486 | 0.70 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593455-A1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | claimed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | claimed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | claimed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | claimed |
| EP-2593455-B1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2015-03-18 | — | — | EP | disclosed |
| EP-2593455-A1 | PURINE COMPOUNDS SELECTIVE FOR I3 P110 DELTA, AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293736-B2 | Purine compounds selective for PI3K P110 delta, and methods of use | F. HOFFMANN LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007493-A1 | PURINE COMPOUNDS SELECTIVE FOR ΡI3Κ P110 DELTA, AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015931-A1 | PURINE COMPOUNDS SELECTIVE FOR PI3K P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CD 2/4885PIK3CA 1/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.